Biomoda’s patented technology, a non-invasive cytology based assay, is designed for cancer screening of large populations at a reasonable cost. Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease only at more advanced stages and are relatively expensive, according to the company.
Daniel Lopez, president of New Mexico Tech, said: “This new R&D collaboration between Biomoda and New Mexico Tech will enable university researchers and students to directly participate in the testing and development of cutting-edge technology which will soon be deployed in the fight against cancer. This new joint venture forged between a public university and a private business promises to be a win-win situation for all involved.”
John Cousins, president of Biomoda, said: “I am particularly pleased to announce our partnership with such a strong research and engineering partner as New Mexico Tech as we move towards commercialization of Biomoda’s early cancer diagnostic technology. The scientists at New Mexico Tech offer a wide range of expertise in biomedical and engineering research programs that will be applied immediately in development of engineering technology for image recognition that is targeted at broad-based screening of large populations for lung cancer.”